http://www.patentbaristas.com/archives/2009/03/03/patent-reform-2009-reactionary-causes/?utm_source=rss&utm_medium=rss&utm_campaign=patent-reform-2009-reactionary-causes Freshly Brewed Bio/Pharma Chat. Served Up Daily. Tue, 07 Feb 2012 11:57:58 +0000 hourly 1 http://wordpress.org/?v=3.3.1 http://www.patentbaristas.com/archives/2009/03/03/patent-reform-2009-reactionary-causes/comment-page-1/#comment-65877 Latest round of patent reform free-for-all « Reading the Fine Print Wed, 04 Mar 2009 19:32:06 +0000 http://www.patentbaristas.com/archives/2009/03/03/patent-reform-2009-reactionary-causes/#comment-65877 [...] Baristas also has a good post describing some of the first reactions from various interest [...] [...] Baristas also has a good post describing some of the first reactions from various interest [...]

]]> http://www.patentbaristas.com/archives/2009/03/03/patent-reform-2009-reactionary-causes/comment-page-1/#comment-65867 Kritik am Patent Reform Act | Artefakte der Zukunft | siebeneinhalb.de - Geistiges Eigentum, Patente, Kultur, Politik, Gesellschaft, Wirtschaft und Technik Wed, 04 Mar 2009 08:29:30 +0000 http://www.patentbaristas.com/archives/2009/03/03/patent-reform-2009-reactionary-causes/#comment-65867 [...] Die Organisation der Forschenden Pharmaunternehmen (Pharmaceutical Research and Manufacturers of America (PhRMA)) sieht es ganz ähnlich und veröffentlichte folgendes Statement: “By lowering the penalties for those found by a court to have infringed another’s patent, the bill would reduce the value of the patents that are the lifeblood of America’s innovative business sectors, which depend on intellectual property protection. Likewise, the bill does not address one of the key recommendations of the National Academy of Sciences, which would reform the inequitable conduct doctrine … A strong and reliable patent system provides American businesses with an incentive that spurs innovation across the country. It is especially important for pharmaceutical and biotechnology innovators that are faced with the daunting average investment of 10 to 15 years and roughly one billion dollars to develop a new drug. We are concerned that the proposed framework will put this important incentive – and, with it, the jobs that are provided by innovative industries – at risk.” (Gefunden bei Patent Baristas) [...] [...] Die Organisation der Forschenden Pharmaunternehmen (Pharmaceutical Research and Manufacturers of America (PhRMA)) sieht es ganz ähnlich und veröffentlichte folgendes Statement: “By lowering the penalties for those found by a court to have infringed another’s patent, the bill would reduce the value of the patents that are the lifeblood of America’s innovative business sectors, which depend on intellectual property protection. Likewise, the bill does not address one of the key recommendations of the National Academy of Sciences, which would reform the inequitable conduct doctrine … A strong and reliable patent system provides American businesses with an incentive that spurs innovation across the country. It is especially important for pharmaceutical and biotechnology innovators that are faced with the daunting average investment of 10 to 15 years and roughly one billion dollars to develop a new drug. We are concerned that the proposed framework will put this important incentive – and, with it, the jobs that are provided by innovative industries – at risk.” (Gefunden bei Patent Baristas) [...]

]]>